Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal

Álvarez, Francisco Blanco; Chevalier, Pierre; Borms, Matthias; Bricout, Hélène; Marques, Cátia; Soininen, Anu; Sainio, Tatu; Petit, C; Courville, Caroline de

doi:10.1080/13696998.2023.2194193

Cited by 10 publications

(9 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…this higher susceptibility to a severe course of the disease is related to both immunosenescence, increasing prevalence of significant comorbidities that are themselves risk factors for influenza-related complications, and a vicious circle of frailty and infections [14][15][16][17].…”

Section: Influenza In Older Peoplementioning

confidence: 99%

“…trivalent inactivated influenza vaccines (iiV3) contain antigens of 2 influenza A viruses (h1n1 and h3n2) and one B virus strain, either yamagata or Victoria line. Quadrivalent inactivated influenza vaccines (iiV4), introduced in the 2017/18 season, contain antigens of 2 A strains and 2 B strains [14,34]. Another vaccine type is live attenuated influenza vaccine (lAiV) administered intranasally and licensed for children aged 2-17 years [28,29].…”

Section: Vaccinations Against Influenzamentioning

confidence: 99%

See 1 more Smart Citation

Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine

Nitsch-Osuch,

Jankowski,

Kokoszka-Paszkot

et al. 2024

fmpcr

View full text Add to dashboard Cite

Annual vaccination is the most effective protection against influenza and its serious complications. it is especially important for people at high risk of severe course of the disease and serious complications: individuals with specific chronic medical conditions, pregnant women, children aged 6-59 months, older people, and healthcare workers. Despite a progressive increase in seasonal vaccine coverage, influenza-related morbidity, mortality, and hospitalization rates remain high and have continued to increase in people aged 65 years and over. standard vaccines against influenza are less efficient in this group due to immunosenescence. consequently, more effective vaccines are needed to prevent influenza and its complications in older adults.

show abstract

Section: Influenza In Older Peoplementioning

confidence: 99%

Section: Vaccinations Against Influenzamentioning

confidence: 99%

Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine

Nitsch-Osuch,

Jankowski,

Kokoszka-Paszkot

et al. 2024

fmpcr

View full text Add to dashboard Cite

show abstract

“… rVE as used in base-case analyses of HD-TIV/HD-QIV compared with TIV/QIV or aTIV/aQIV [ 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 ]. Note: no value indicates that a comparison was not evaluated.…”

Section: Cost-effectiveness Studies With Enhanced Influenza Vaccinesmentioning

confidence: 99%

“…The rVE estimate of 24.2% for HD-TIV/HD-QIV versus TIV/QIV for LCI cases, based on results from the FIM12 RCT [50], was consistently used in CEA comparing HD-TIV/HD-QIV versus TIV/QIV, and used in CEA that indirectly compared the rVE of HD-TIV/HD-QIV versus aTIV/aQIV (Tables 2B and 3B; Figure 2). [65][66][67][68][69][70][71][72][73][74][75][76][77][78][79][80][81]. Note: no value indicates that a comparison was not evaluated.…”

Section: Comparison Between Cea For Enhanced and Standard Vaccinesmentioning

confidence: 99%

See 1 more Smart Citation

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

et al. 2023

View full text Add to dashboard Cite

Influenza vaccination can benefit most populations, including adults ≥ 65 years of age, who are at greater risk of influenza-related complications. In many countries, enhanced vaccines, such as adjuvanted, high-dose, and recombinant trivalent/quadrivalent influenza vaccines (aTIV/aQIV, HD-TIV/HD-QIV, and QIVr, respectively), are recommended in older populations to provide higher immunogenicity and increased relative vaccine efficacy/effectiveness (rVE) than standard-dose vaccines. This review explores how efficacy and effectiveness data from randomized controlled trials and real-world evidence (RWE) are used in economic evaluations. Findings from published cost-effectiveness analyses (CEA) on enhanced influenza vaccines for older adults are summarized, and the assumptions and approaches used in these CEA are assessed alongside discussion of the importance of RWE in CEA. Results from many CEA showed that adjuvanted and high-dose enhanced vaccines were cost-effective compared with standard vaccines, and that differences in rVE estimates and acquisition price may drive differences in cost-effectiveness estimates between enhanced vaccines. Overall, RWE and CEA provide clinical and economic rationale for enhanced vaccine use in people ≥ 65 years of age, an at-risk population with substantial burden of disease. Countries that consider RWE when making vaccine recommendations have preferentially recommended aTIV/aQIV, as well as HD-TIV/HD-QIV and QIVr, to protect older individuals.

show abstract

New Vaccines for Chronic Respiratory Patients

Mallah,

Urbieta,

Rivero-Calle

et al. 2024

Archivos de Bronconeumología

View full text Add to dashboard Cite

Cost-effectiveness of influenza vaccination with a high dose quadrivalent vaccine of the elderly population in Belgium, Finland, and Portugal

Cited by 10 publications

References 41 publications

Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine

Towards better protection of older people against influenza and its complications. Polish recommendations for HD influenza vaccine

Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion

New Vaccines for Chronic Respiratory Patients

Contact Info

Product

Resources

About